VolitionRx to Present Data Demonstrating Accuracy of NuQ® Blood Test in Detecting Colorectal Cancer at World Endoscopy Organization (WEO) Meeting

Dr. Jason Terrell, Chief Medical Officer & Head of U.S. Operations, to present prior to Digestive Disease Week (DDW) in San Diego, CA

NAMUR, Belgium, May 19, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced that its Chief Medical Officer & Head of U.S. Operations, Dr. Jason Terrell, is to present at the World Endoscopy Organization (WEO) Colorectal Cancer Screening Committee Meeting on May 20, 2016, which precedes Digestive Disease Week (DDW), being held May 21-24, 2016 in San Diego, CA. Dr. Terrell will present data from three clinical trials evaluating the Company’s NuQ® blood tests for the detection of colorectal cancer and adenomas, or pre-cancerous polyps.

The key objectives of the WEO CRC meeting are to provide updates on recent advances in CRC screening, seek advice and comments on future initiatives, and reach consensus on controversial areas. Digestive Disease Week is the world’s largest gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

Dr. Terrell's presentation will include three data sets from VolitionRx: results from its first completed prospective clinical trial in colorectal cancer, a 121-subject study at CHU Dinant Godinne – UCL Namur, in which a panel of four NuQ® biomarker assays demonstrated 91% sensitivity at 90% specificity, including a 67% detection of high-risk adenomas; results from its first completed retrospective clinical trial targeted at detecting adenomas, a 430-subject study at Hvidovre Hospital, University of Copenhagen, Denmark, in which a NuQ® panel demonstrated 75% sensitivity at 78% specificity for high-risk adenomas and 86% sensitivity for stage I-colorectal cancer; and interim results from a retrospective 4,800-subject study at Hvidovre Hospital, in which a NuQ® panel demonstrated 81% sensitivity for colorectal cancer, 63% sensitivity for benign polyps, and 67% sensitivity for high-risk adenomas.

Details of Dr. Terrell's presentation at WEO follow:
"We are honored to take part in this prestigious discussion on the current and future state of colorectal cancer screening," commented Dr. Terrell. "To date, VolitionRx has demonstrated across several clinical trials that our NuQ® blood test is able to accurately detect colorectal cancer with high sensitivity and specificity, as well as further distinguish between cancer, adenomas and healthy subjects. We believe we have a very promising test for accurately diagnosing CRC through a non-invasive, affordable method that can be performed on a small amount of blood collected in a routine blood draw."

Results from on-going clinical trials assessing the effectiveness of VolitionRx's biomarker assays, include:

**Colorectal cancer and pre-cancerous colorectal adenomas**

- Results from a retrospective study of 430 patients referred for colonoscopy (Hvidovre Hospital, University of Copenhagen, Denmark), released February 17, 2016: Panel of five NuQ® biomarker assays demonstrated 75% accuracy in detecting highest-risk pre-cancerous colorectal adenomas and also detected 86% of early (stage I) colorectal cancers at 78% specificity. ([http://www.volitionrx.com/news/press-releases/detail/550/volitionrx-demonstrates-75-accuracy-in-detecting](http://www.volitionrx.com/news/press-releases/detail/550/volitionrx-demonstrates-75-accuracy-in-detecting))

**Pancreatic cancer**

• Interim results from a 4,800 patient retrospective symptomatic population study (Hvidovre Hospital, University of Copenhagen, Denmark), released October 22, 2015: Panel of two NuQ® biomarker assays and the classical cancer marker CEA (carcino-embryonic antigen) detected 95% of pancreatic cancers at 84% specificity. (http://www.volitionrx.com/news/press-releases/detail/535/volitionrx-demonstrates-nuq-blood-test-detects-95-of)

Prostate Cancer

• Results from a 537-patient retrospective study (Surrey Cancer Research Institute at University of Surrey, United Kingdom), released April 20, 2016 at the AACR Annual Meeting: A single NuQ® biomarker assay detected 71% of early stage I prostate cancer cases and 86% of late stage IV prostate cancer at 93% specificity, which is significantly higher than the commonly-used PSA test reported to detect 53% of prostate cancers at 73% specificity. (http://www.volitionrx.com/news/press-releases/detail/561/volitionrx-announces-study-results-showing-nuq-blood-test)

Lung cancer

• Interim results (73 of 240 patients collected and assessed) from a prospective study (Liège University Hospital, Belgium), released November 19, 2015: Panel of four NuQ® biomarker assays detected 93% of lung cancers at 91% specificity and differentiated lung cancer from the common lung disease, COPD. (http://www.volitionrx.com/news/press-releases/detail/540/volitionrx-demonstrates-nuq-blood-test-detects-lung)

Idiopathic Pulmonary Fibrosis

• Results from a retrospective study of 78 patients referred for colonoscopy (Liège University Hospital, Belgium), released March 9, 2016: Preliminary data demonstrated 86% accuracy in detecting Idiopathic Pulmonary Fibrosis, a fatal lung disease, at 80% specificity. (http://www.volitionrx.com/news/press-releases/detail/551/preliminary-data-demonstrates-86-accuracy-in-detecting)

About VolitionRx

VolitionRx is a life sciences company focused on developing diagnostic tests for cancer and other conditions. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.

VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

Visit VolitionRx's website (http://www.volitionrx.com) or connect with us via Twitter, LinkedIn, Facebook or YouTube.
Media Contacts
Louise Day, VolitionRx
L.day@volitionrx.com
+44 (0) 7557 774620

Kirsten Thomas, The Ruth Group
kthomas@theruthgroup.com
+1 (508) 280-6592

Investor Contacts
Scott Powell, VolitionRx
S.Powell@volitionrx.com
+1 (646) 650-1351

Lee Roth, The Ruth Group
lroth@theruthgroup.com
+1 (646) 536-7012

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of the Company's bodily-fluid-based diagnostic tests as well as the Company's ability to develop and successfully commercialize such test platforms for early detection of cancer. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include the Company's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company's development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics®, NuQ® and HyperGenomics® and their respective logos are trademarks
and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.


SOURCE VolitionRx Ltd